These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 31325638

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW, Lynch KD.
    Br Med Bull; 2020 May 15; 133(1):95-104. PubMed ID: 32282030
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S, Di Giorgio C, Distrutti E.
    Handb Exp Pharmacol; 2019 May 15; 256():283-295. PubMed ID: 31201552
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
    Marchianò S, Biagioli M, Roselli R, Zampella A, Di Giorgio C, Bordoni M, Bellini R, Morretta E, Monti MC, Distrutti E, Fiorucci S.
    FASEB J; 2022 Jan 15; 36(1):e22060. PubMed ID: 34862975
    [Abstract] [Full Text] [Related]

  • 13. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A, Biagioli M, Marchianò S, Scarpelli P, Zampella A, Limongelli V, Fiorucci S.
    Pharmacol Res; 2018 May 15; 131():17-31. PubMed ID: 29530598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.
    Gastroenterology; 2013 Sep 15; 145(3):574-82.e1. PubMed ID: 23727264
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T, Itoh M, Suganami T, Kanai S, Shirakawa I, Sakai T, Asakawa M, Yoneyama T, Kai T, Ogawa Y.
    Sci Rep; 2018 May 25; 8(1):8157. PubMed ID: 29802399
    [Abstract] [Full Text] [Related]

  • 20. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH, Lindor KD.
    Expert Opin Pharmacother; 2016 Sep 25; 17(13):1809-15. PubMed ID: 27468093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.